BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
What happened
Egetis Therapeutics (Nasdaq Stockholm: EGTX) announced Monday, September 28, 2026, that the FDA has approved EMCITATE (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency (Allan–Herndon–Dudley syndrome). It is the first and only FDA-approved treatment for this condition in the United States.
• First-ever approved treatment for MCT8 deficiency, a rare X-linked disorder with median life expectancy of about 35 years
• FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) with the approval
• Approval backed by the ReTRIACt, Triac Trial I and II studies plus Erasmus Medical Center cohorts and a U.S. expanded access program
• Egetis launches the Egetis RareLink patient support program in partnership with PANTHERx Rare
• Company hosts an analyst and investor call Tuesday, September 29 at 8:00 am CESTWhy it matters
Rare-disease approvals matter to investors for two reasons: PRV vouchers can be sold for meaningful cash (historically nine-figure sums), and first-in-class approvals in severe pediatric diseases tend to command premium pricing with little competition. EMCITATE addresses a disease with no prior disease-modifying option — severe neurodevelopmental impairment driven by impaired thyroid-hormone transport.
One caveat for U.S. investors: Egetis trades on Nasdaq Stockholm (EGTX), not on a U.S. exchange, so the FDA approval moves a European-listed stock. Watch how the company handles U.S. commercialization through its PANTHERx Rare partnership.
What to watch
Tuesday’s analyst call for launch and pricing details, the U.S. commercial ramp over the coming quarters, and any PRV sale — those proceeds can fund Egetis’s pipeline. It also caps a busy FDA day: Ultragenyx won approval for the first-ever Sanfilippo syndrome gene therapy hours earlier.
Related reading: another first-ever rare-disease approval from the same day — https://bullounge.com/forums/topic/ultragenyx-wins-fda-approval-for-first-ever-sanfilippo-syndrome-type-a-treatment/
Should priority review vouchers make rare-disease biotechs more attractive to investors, or is the commercial risk still too high? Share your view below.
Auto-posted by the Bull Lounge news desk. Not financial advice.
Log in to vote
